120 related articles for article (PubMed ID: 32564869)
1. Phase I dose escalating study of oral cyclophosphamide in tumour-bearing cats.
Chan CM; Rassnick KM; Frimberger AE; Nguyen SM; Moore AS
Vet J; 2020 Apr; 258():105450. PubMed ID: 32564869
[TBL] [Abstract][Full Text] [Related]
2. Dosage escalation of intravenous cyclophosphamide in cats with cancer.
Moore AS; Frimberger AE; Chan CM
Vet J; 2018 Dec; 242():39-43. PubMed ID: 30503542
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of low-dose metronomic (LDM) cyclophosphamide toxicity in cats with malignant neoplasia.
Leo C; Stell A; Borrego J; Martinez de Merlo E; Ruess-Melzer K; Lara-Garcia A
J Feline Med Surg; 2014 Aug; 16(8):671-8. PubMed ID: 24423814
[TBL] [Abstract][Full Text] [Related]
4. Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumors.
Talbot SM; Westerman DA; Grigg AP; Toner GC; Wolf M; Bishop J; McKendrick J; Zalcberg J; Levi J; Fox RM; Green MD
Ann Oncol; 1999 Aug; 10(8):907-14. PubMed ID: 10509151
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical evaluation of carboplatin in tumor-bearing cats: a Veterinary Cooperative Oncology Group study.
Kisseberth WC; Vail DM; Yaissle J; Jeglum KA; Couto CG; Ward H; Khanna C; Obradovich JE
J Vet Intern Med; 2008; 22(1):83-8. PubMed ID: 18289293
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical trial of vinorelbine in tumor-bearing cats.
Pierro JA; Mallett CL; Saba CF
J Vet Intern Med; 2013; 27(4):943-8. PubMed ID: 23662626
[TBL] [Abstract][Full Text] [Related]
7. Phase I evaluation of CCNU (lomustine) in tumor-bearing cats.
Rassnick KM; Gieger TL; Williams LE; Ruslander DM; Northrup NC; Kristal O; Myers NC; Moore AS
J Vet Intern Med; 2001; 15(3):196-9. PubMed ID: 11380027
[TBL] [Abstract][Full Text] [Related]
8. Treatment of feline lymphoma using a 12-week, maintenance-free combination chemotherapy protocol in 26 cats.
Limmer S; Eberle N; Nerschbach V; Nolte I; Betz D
Vet Comp Oncol; 2016 Aug; 14 Suppl 1():21-31. PubMed ID: 24548273
[TBL] [Abstract][Full Text] [Related]
9. Therapy for Australian cats with lymphosarcoma.
Malik R; Gabor LJ; Foster SF; McCorkell BE; Canfield PJ
Aust Vet J; 2001 Dec; 79(12):808-17. PubMed ID: 11837901
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial and pharmacokinetic analysis of ifosfamide in cats with sarcomas.
Rassnick KM; Moore AS; Northrup NC; Kristal O; Beaulieu BB; Lewis LD; Page RL
Am J Vet Res; 2006 Mar; 67(3):510-6. PubMed ID: 16506919
[TBL] [Abstract][Full Text] [Related]
11. Potency and stability of compounded cyclophosphamide: a pilot study.
Robat C; Budde J
Vet Comp Oncol; 2017 Sep; 15(3):706-709. PubMed ID: 27028306
[TBL] [Abstract][Full Text] [Related]
12. Hematological toxicity and therapeutic efficacy of lomustine in 20 tumor-bearing cats: critical assessment of a practical dosing regimen.
Fan TM; Kitchell BE; Dhaliwal RS; Jones PD; Hintermeister JG; Paria BC
J Am Anim Hosp Assoc; 2002; 38(4):357-63. PubMed ID: 12118689
[TBL] [Abstract][Full Text] [Related]
13. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens.
Emmenegger U; Man S; Shaked Y; Francia G; Wong JW; Hicklin DJ; Kerbel RS
Cancer Res; 2004 Jun; 64(11):3994-4000. PubMed ID: 15173013
[TBL] [Abstract][Full Text] [Related]
14. Low-dose metronomic delivery of cyclophosphamide is less detrimental to granulosa cell viability, ovarian function, and fertility than maximum tolerated dose delivery in the mouse.
Dynes J; Osz K; Hooper A; Petrik J
Biol Reprod; 2017 Sep; 97(3):449-465. PubMed ID: 29024988
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of, and toxicoses associated with, oral idarubicin administration in cats with neoplasia.
Moore AS; Ruslander D; Cotter SM; Rand WM; L'Heureux DA
J Am Vet Med Assoc; 1995 May; 206(10):1550-4. PubMed ID: 7775231
[TBL] [Abstract][Full Text] [Related]
16. Intravenous administration of docetaxel to cats with cancer.
Shiu KB; McCartan L; Kubicek L; Vail DM
J Vet Intern Med; 2011; 25(4):916-9. PubMed ID: 21615496
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
Itoh K; Ohtsu T; Fukuda H; Sasaki Y; Ogura M; Morishima Y; Chou T; Aikawa K; Uike N; Mizorogi F; Ohno T; Ikeda S; Sai T; Taniwaki M; Kawano F; Niimi M; Hotta T; Shimoyama M; Tobinai K;
Ann Oncol; 2002 Sep; 13(9):1347-55. PubMed ID: 12196359
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy in feline lymphoma: treatment outcome, tolerability, and duration in 23 cats.
Simon D; Eberle N; Laacke-Singer L; Nolte I
J Vet Intern Med; 2008; 22(2):394-400. PubMed ID: 18312554
[TBL] [Abstract][Full Text] [Related]
19. Treatment-related toxicities in tumor-bearing cats treated with temozolomide alone or in combination with doxorubicin: a pilot assessment.
Gagnon J; Dervisis NG; Kitchell BE
J Feline Med Surg; 2012 Aug; 14(8):560-5. PubMed ID: 22496148
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of high dose epirubicin in combination with cyclophosphamide in patients with advanced breast cancer.
Levi JA; Beith JM; Snyder RD; Tattersall MH; Bell D; Wheeler H
Aust N Z J Med; 1995 Oct; 25(5):474-8. PubMed ID: 8588767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
